Status:
RECRUITING
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Chronic Myelogenous Leukemia
Eligibility:
All Genders
Brief Summary
In this study researchers propose to do a chart review of all patients that are treated outside of a clinical trial with imatinib, dasatinib, nilotinib, or any other tyrosine kinase inhibitor that bec...
Detailed Description
PATIENT POPULATION: All patients with CML in any phase of the disease (chronic, accelerated or blast phase) that has received treatment with any tyrosine kinase inhibitor (eg, imatinib, dasatinib, ni...
Eligibility Criteria
Inclusion
- All patients with CML in any phase of the disease (chronic, accelerated or blast phase) that has received treatment with any FDA-approved tyrosine kinase inhibitor (eg, imatinib, dasatinib, nilotinib) not on an MDACC clinical trial regardless of prior treatment history that has had at least one clinic visit at MDACC will be eligible.
Exclusion
- N/A
Key Trial Info
Start Date :
June 8 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2030
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT00816114
Start Date
June 8 2005
End Date
April 30 2030
Last Update
October 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030